Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: Results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study

Heart

Volumn 98, Issue 23, 2012, Pages 1710-1715

  Mannacio, Vito Antonio ^a   Di Tommaso, Luigi ^a   Antignan, Anita ^b   De Amicis, Vincenzo ^a   Vosa, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHEST TUBE; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT OCCLUSION; HUMAN; ISCHEMIC HEART DISEASE; ITALY; MAJOR CLINICAL STUDY; MALE; OFF PUMP CORONARY SURGERY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; SURGICAL DRAINAGE; THROMBOCYTE FUNCTION; URINARY TRACT HEMORRHAGE; VASCULAR PATENCY;

ACUTE CORONARY SYNDROME; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS, OFF-PUMP; CORONARY OCCLUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84869174129     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302449     Document Type: Article

References (30)

1. Mangano DT; Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-17.
2. Karzai W, Priebe HJ. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2003;348:1057-9.
3. Stein PD, Schünemann HJ, Dalen JE, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):600-8.
4. Patel JH, Stoner JA, Owora A, et al. Evidence for using clopidogrel alone or in addition to aspirin in post coronary artery bypass surgery patients. Am J Cardiol 2009;103:1687-93.
5. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995;11:221-7.
6. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
7. Wang Z, Gao F, Men J, et al. Aspirin resistance in off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg 2012;41:108-12.
8. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97:983-90.
9. Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011;97:1239-44.
10. Zimmermann N, Kurt M, Wenk A, et al. Is cardiopulmonary bypass a reason for aspirin resistance after coronary artery bypass grafting? Eur J Cardiothorac Surg 2005;27:606-10.
11. Weber M, Bhatt DL, Brennan DM, et al. High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart 2011;97:626-31.
12. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-77.
13. Oh IY, Park KW, Kang SH, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2012;98:139-44.
14. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
15. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-8.
16. Patrono C, Coller B, Dalen JE, et al. Platelet active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119(1 Suppl):39S-63S.
17. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13.
18. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007;119:277-84.
19. van Werkum JW, van der Stelt CA, Seesing TH, et al. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006;4:2516-18.
20. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26.
21. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of myocardial infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95.
22. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-10.
23. Loscalzo J. Vascular matrix and vein graft failure. Is the message in the medium? Circulation 2000;101 :221-3.
24. FitzGibbon GM, Leach AJ, Keon WJ, et al. Coronary bypass graft fate. Angiographic study of 1,179 vein grafts early, one year, and five year after operation. J Thorac Cardiovasc Surg 1986;91:773-8.
25. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
26. Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary artery bypass surgery: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. N Engl J Med 2002;324:1309-17.
27. Kulik A, Le May MR, Voisine P, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation 2010;122:2680-7.
28. Ibrahim K, Tjomsland O, Halvorsen D, et al. Effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery. Heart Surg Forum 2006;9:E581-6.
29. Gurbuz AT, Zia AA, Vuran AC, et al. Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. Eur J Cardiothorac Surg 2006;29:190-5.
30. Gao G, Zheng Z, Pi Y, et al . Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 2010;56:1639-43.